By contrast, mice bearing 3LL/GM‐CSF tumors showed profiles comparable to that of human hyperprogressors, characterized by an exponential acceleration of tumor growth (P < 0.0001) tumor growth, shortened survival (median survival of 14 days vs. 17 days of wild‐type control, P = 0.009) and overwhelming numbers of MDSCs (58.52% ± 9.17 of Ly6G+ cells). The gene discussed is CSF2; the disease is neoplasm.